Who owns GAIN THERAPEUTICS INC?
- Ticker: GANX
- CUSIP Number: 36269b105
Tip: Access positions for across all investors
Analyze quarterly positions in Gain Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Gain Therapeutics stock
Who bought or sold GAIN THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Marshall Wace | 1.7M | $5.4M | 849% | Dec 2025 |
|
| Potomac Capital Management | 1.0M | $3.3M | 100% | Dec 2025 |
|
| Susquehanna International | 729k | $2.3M | 806% | Dec 2025 |
|
| Jones Financial Companies, L.L | 702k | $2.3M | 4% | Dec 2025 |
|
| Vanguard Group | 570k | $1.8M | 7% | Dec 2025 |
|
| Cambridge Investment Research Advisors | 569k | $1.1M | 0% | Mar 2026 |
|
| DME Capital Management | 566k | $1.1M | 0% | Mar 2026 |
|
| Geode Capital Management | 447k | $869k | 12% | Mar 2026 |
|
| Vanguard Capital Management | 400k | $776k | 100% | Mar 2026 |
|
| GSA Capital Partners | 313k | $606k | 1426% | Mar 2026 |
|
| Jane Street | 256k | $496k | 5% | Mar 2026 |
|
| Vanguard Fiduciary Trust | 230k | $446k | 100% | Mar 2026 |
|
| BlackRock | 225k | $437k | 7% | Mar 2026 |
|
| UBS Group | 221k | $428k | 172% | Mar 2026 |
|
| Cresset Asset Management | 160k | $310k | 0% | Mar 2026 |
|
| State Street Corporation | 158k | $507k | 73% | Dec 2025 |
|
| Morgan Stanley | 140k | $271k | -5% | Mar 2026 |
|
| Stratos Wealth Partners | 132k | $255k | 100% | Mar 2026 |
|
| LPL Financial | 104k | $202k | -2% | Mar 2026 |
|
| Northern Trust | 102k | $328k | 15% | Dec 2025 |
|
| Colony | 78k | $251k | 100% | Dec 2025 |
|
| Citadel Advisors | 71k | $137k | -9% | Mar 2026 |
|
| Simplex Trading | 48k | $154k | 100% | Dec 2025 |
|
| Springbok Capital Management | 36k | $115k | 0% | Dec 2025 |
|
| Bridgeway Capital Management | 30k | $97k | 0% | Dec 2025 |
|
| Commonwealth Equity Services | 30k | $58k | 134% | Mar 2026 |
|
| Apollon Wealth Management | 27k | $51k | 34% | Mar 2026 |
|
| Schonfeld Strategic Advisors | 25k | $48k | 100% | Mar 2026 |
|
| Lighthouse Investment Partners | 23k | $74k | 100% | Dec 2025 |
|
| Oliver Luxxe Assets | 20k | $39k | 0% | Mar 2026 |
|
| Vanguard Global Advisers | 18k | $36k | 100% | Mar 2026 |
|
| Renaissance Technologies | 17k | $56k | -86% | Dec 2025 |
|
| Sontag Advisory | 17k | $33k | 0% | Mar 2026 |
|
| Benedict Financial Advisors | 16k | $30k | -59% | Mar 2026 |
|
| Sandhill Capital Partners | 15k | $30k | 0% | Mar 2026 |
|
| Millington Financial Advisors | 15k | $29k | 100% | Mar 2026 |
|
| Engineers Gate Manager | 15k | $47k | 100% | Dec 2025 |
|
| Kestra Advisory Services | 12k | $23k | 0% | Mar 2026 |
|
| Wells Fargo & Company | 11k | $21k | 317% | Mar 2026 |
|
| Goss Wealth Management | 11k | $21k | 0% | Mar 2026 |
|
| Tower Research Capital | 6.9k | $22k | 232% | Dec 2025 |
|
| Group One Trading | 6.4k | $12k | -88% | Mar 2026 |
|
| Larson Financial Group | 10.00 | $32.000000 | 100% | Dec 2025 |
|
| Citigroup | 1.00 | $2.000000 | 100% | Mar 2026 |
|
Who sold out of Gain Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Hrt Financial | Dec 2025 | 56k | $179k |
| XTX Topco | Sep 2025 | 54k | $96k |
| Virtu Financial | Sep 2025 | 54k | $96k |
| OMERS Administration Corporation | Dec 2025 | 37k | $120k |
| Goldman Sachs Group | Dec 2025 | 33k | $105k |
| Point72 Asset Management | Dec 2025 | 33k | $105k |
| Jpmorgan Chase & Co | Sep 2025 | 26k | $47k |
| Wealth Enhancement Advisory Services | Dec 2025 | 16k | $40k |
| Millennium Management | Dec 2025 | 14k | $45k |
| Sprott | Dec 2025 | 12k | $39k |
| Creekmur Asset Management | Sep 2025 | 4.4k | $7.9k |
| MAI Wealth Advisors | Dec 2025 | 4.4k | $14k |
| Bnp Paribas Arbitrage, Snc | Dec 2025 | 2.4k | $7.7k |
| FNY Investment Advisers | Dec 2025 | 2.0k | $6.0k |
| State of Wyoming | Dec 2025 | 1.4k | $4.6k |